Sofpironium
Sofpironium is a novel anticholinergic agent in the form of a soft drug specifically designed for topical application to reduce sweating in primary axillary hyperhidrosis. By blocking muscarinic acetylcholine receptors on eccrine sweat glands, it inhibits sweat secretion locally, with its retro-metabolic design ensuring rapid systemic inactivation to minimize systemic anticholinergic side effects. It is applied topically as a gel formulation.
Peso molecular
390,5000 g/mol
LogP
3,30
TPSA
72,80 Ų
Regla de cinco de Lipinski
Cumple
Mecanismo de acción
Applied directly to the skin or mucous membranes, where it exerts its therapeutic effect locally at the site of application with minimal systemic absorption.
Pharmacokinetics (PK)
Pharmacodynamics (PD)
Applied directly to the skin or mucous membranes, where it exerts its therapeutic effect locally at the site of application with minimal systemic absorption.
Estructura 2D
Cite this structure
Embed this structure
SMILES
CCOC(=O)C[N+]1(C)CC[C@@H](OC(=O)[C@](O)(c2ccccc2)C2CCCC2)C1
InChI
InChI=1S/C22H32NO5/c1-3-27-20(24)16-23(2)14-13-19(15-23)28-21(25)22(26,18-11-7-8-12-18)17-9-5-4-6-10-17/h4-6,9-10,18-19,26H,3,7-8,11-16H2,1-2H3/q+1/t19-,22+,23?/m1/s1
Molecular Formula
C22H32NO5+
HBD / HBA
1 / 5
Enlaces Rotables
9
Átomos Pesados
28
No targets recorded
Target interaction data is not yet available for this drug.
No interactions recorded
Drug interaction data is not yet available for this compound.
No side effects recorded
Side effect data is not yet available for this drug.
Preguntas frecuentes
Sofpironium is a novel anticholinergic agent in the form of a soft drug specifically designed for topical application to reduce sweating in primary axillary hyperhidrosis. By blocking muscarinic acetylcholine receptors on eccrine sweat glands, it inhibits sweat secretion locally, with its retro-metabolic design ensuring rapid systemic inactivation to minimize systemic anticholinergic side effects. It is applied topically as a gel formulation.
Applied directly to the skin or mucous membranes, where it exerts its therapeutic effect locally at the site of application with minimal systemic absorption.
Yes, Sofpironium is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.
References & Data Sources
- ChEMBL — European Bioinformatics Institute (EBI). CHEMBL3707224. Open-access bioactivity database.
- PubChem — National Center for Biotechnology Information (NCBI). CID 86301317. Chemical information database.
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.
Embed This Widget
Add the script tag and a data attribute to embed this widget.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<div data-drugfyi="drug" data-slug="sofpironium"></div>Embed via iframe for maximum compatibility.
<iframe src="https://drugfyi.com/iframe/drug/sofpironium/" width="420" height="400" frameborder="0" style="border:0;border-radius:10px;max-width:100%" loading="lazy"></iframe>Paste this URL in WordPress, Medium, or any oEmbed-compatible platform.
https://drugfyi.com/drug/sofpironium/Add a dynamic SVG badge to your README or docs.
[](https://drugfyi.com/drug/sofpironium/)Use the native HTML custom element.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<drugfyi-drug slug="sofpironium"></drugfyi-drug>